"Rusan Pharma Allocates INR 300 Crores for New API Facility in Pithampur, Madhya Pradesh"

Pithampur, Madhya Pradesh, witnessed the inauguration of Rusan Pharma's state-of-the-art active pharmaceutical ingredient (API) facility recently. The pharmaceutical company has invested Rs. 300 crore in this new facility, situated within the Pithampur Special Economic Zone (SEZ), marking a significant expansion for the company.

The API facility is poised to contribute significantly to Rusan Pharma's production capabilities, with an annual output capacity of 400 metric tonnes of APIs. This expansion is expected to create over 300 job opportunities in the region.

The strategic move aligns with Rusan Pharma's commitment to meeting the rising demand for its addiction treatment and pain management products in both domestic and international markets. The company is renowned for its innovative pharmaceutical solutions, including Buprenorphine Sublingual and Buprenorphine Naloxone Sublingual Tablets for drug abuse treatment, Apomorphine Injections for Parkinson's treatment, and indigenous formulations of Fentanyl, Buprenorphine, and Lidocaine transdermal patches catering to moderate to severe pain. Additionally, Rusan Pharma produces Nicotine transdermal patches to aid in tobacco cessation.

Kunal Saxena, the Managing Director of Rusan Pharma, shared insights into the significant investment, stating, “With an investment of about Rs. 300 crore in two phases, this new API facility will expand our current API manufacturing capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur. Our new plant features five modular API manufacturing blocks with dedicated suites for finished API production.”

The company emphasized its adherence to current Good Manufacturing Practice (cGMP) standards, ensuring the highest quality for its APIs and finished formulations. Rusan Pharma's facilities have received cGMP approvals from various global health authorities, including Health Canada, the Therapeutic Goods Administration (TGA) of Australia, the South African Health Products Regulatory Authority (SAPHRA), the European Union (EU), the United Arab Emirates (UAE), and Russia. The company affirms that these approvals position them to meet 90 percent of the global demand.

The inauguration of the Pithampur facility represents a significant milestone for Rusan Pharma as it reinforces its commitment to advancing pharmaceutical manufacturing capabilities and addressing critical healthcare needs on a global scale.

BS